Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil EC50 for Awake Nasotracheal Intubation
NCT01052324Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remifentanil in cervical disc herniation (CDH), cervical spinal stenosis (CSS) and cervical spine injury, sponsored by Yonsei University. Primary endpoint: Effective Concentration 50%. Started Mar 2010; status: completed.
02
Drugs
remifentanil
03
Conditions
cervical disc herniation (CDH)cervical spinal stenosis (CSS)cervical spine injury
Beyond the preview
Go deeper on NCT01052324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052324.